G M Tozer

Summary

Affiliation: University of Sheffield
Country: UK

Publications

  1. pmc The endothelin B (ETB) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: potential for selective tumour blood flow modification
    M Cemazar
    Gray Cancer Institute, Mount Vernon Hospital, PO Box 100, Northwood, Middlesex HA6 2JR, UK
    Br J Cancer 93:98-106. 2005
  2. pmc Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression
    Gabi U Dachs
    Angiogenesis Research Group, Department of Pathology, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
    BMC Cancer 6:280. 2006
  3. pmc Direct visualization of electroporation-assisted in vivo gene delivery to tumors using intravital microscopy - spatial and time dependent distribution
    Maja Cemazar
    Department of Experimental Oncology, Institute of Oncology, Zaloska 2, SI 1000 Ljubljana, Slovenia
    BMC Cancer 4:81. 2004
  4. doi request reprint Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors
    Gillian M Tozer
    Cancer Research UK Tumour Microcirculation Group, Academic Unit of Surgical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, United Kingdom
    Cancer Res 68:2301-11. 2008
  5. doi request reprint Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses
    Gillian M Tozer
    Cancer Research UK Tumour Microcirculation Group, Academic Unit of Surgical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, United Kingdom
    Clin Cancer Res 15:3781-90. 2009
  6. ncbi request reprint Disrupting tumour blood vessels
    Gillian M Tozer
    Academic Unit of Surgical Oncology, Division of Clinical Sciences, University of Sheffield, Floor K, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK
    Nat Rev Cancer 5:423-35. 2005
  7. doi request reprint Tumour vascular disrupting agents: combating treatment resistance
    G M Tozer
    University of Sheffield, Academic Unit of Surgical Oncology, K Floor, School of Medicine and Biomedical Sciences, Beech Hill Road, Sheffield S10 2RX, UK
    Br J Radiol 81:S12-20. 2008
  8. ncbi request reprint Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability
    G M Tozer
    Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, HA6 2JR, United Kingdom
    Cancer Res 61:6413-22. 2001
  9. pmc Reduced capacity of tumour blood vessels to produce endothelium-derived relaxing factor: significance for blood flow modification
    G M Tozer
    Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, UK
    Br J Cancer 74:1955-60. 1996
  10. ncbi request reprint Vascular response of tumour and normal tissues to endothelin-1 following antagonism of ET(A) and ET(B) receptors in anaesthetised rats
    K M Bell
    Tumour Microcirculation Group, Mount Vernon Hospital, Northwood, UK
    Int J Cancer 73:283-9. 1997

Detail Information

Publications51

  1. pmc The endothelin B (ETB) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: potential for selective tumour blood flow modification
    M Cemazar
    Gray Cancer Institute, Mount Vernon Hospital, PO Box 100, Northwood, Middlesex HA6 2JR, UK
    Br J Cancer 93:98-106. 2005
    ..Expression levels of ET(B) receptors on the tumour vasculature could be useful for predicting which tumours are likely to respond to IRL 1620...
  2. pmc Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression
    Gabi U Dachs
    Angiogenesis Research Group, Department of Pathology, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
    BMC Cancer 6:280. 2006
    ..Gene regulation under tumour conditions is governed by hypoxia inducible factor 1 (HIF-1), controlling angiogenic and metastatic pathways...
  3. pmc Direct visualization of electroporation-assisted in vivo gene delivery to tumors using intravital microscopy - spatial and time dependent distribution
    Maja Cemazar
    Department of Experimental Oncology, Institute of Oncology, Zaloska 2, SI 1000 Ljubljana, Slovenia
    BMC Cancer 4:81. 2004
    ..Intravital microscopy of tumors growing in dorsal skin fold window chambers is a useful method for monitoring gene transfection, since it allows non-invasive dynamic monitoring of gene expression in tumors in a live animal...
  4. doi request reprint Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors
    Gillian M Tozer
    Cancer Research UK Tumour Microcirculation Group, Academic Unit of Surgical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, United Kingdom
    Cancer Res 68:2301-11. 2008
    ..Results imply differences in signaling pathways between VEGF isoforms and suggest that VEGF isoforms might be useful in vascular-disrupting cancer therapy to predict tumor susceptibility to VDAs...
  5. doi request reprint Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses
    Gillian M Tozer
    Cancer Research UK Tumour Microcirculation Group, Academic Unit of Surgical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, United Kingdom
    Clin Cancer Res 15:3781-90. 2009
    ..The therapeutic potential of combining the prototype tumor vascular-disrupting agent combretastatin A-4 3-O-phosphate (CA-4-P) with systemic nitric oxide synthase (NOS) inhibition was investigated preclinically...
  6. ncbi request reprint Disrupting tumour blood vessels
    Gillian M Tozer
    Academic Unit of Surgical Oncology, Division of Clinical Sciences, University of Sheffield, Floor K, Royal Hallamshire Hospital, Sheffield, S10 2JF, UK
    Nat Rev Cancer 5:423-35. 2005
    ....
  7. doi request reprint Tumour vascular disrupting agents: combating treatment resistance
    G M Tozer
    University of Sheffield, Academic Unit of Surgical Oncology, K Floor, School of Medicine and Biomedical Sciences, Beech Hill Road, Sheffield S10 2RX, UK
    Br J Radiol 81:S12-20. 2008
    ..In summary, VDAs provide a novel approach to cancer treatment, which should effectively complement standard treatments, if treatment resistance is addressed by judicious combination treatment strategies...
  8. ncbi request reprint Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability
    G M Tozer
    Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, HA6 2JR, United Kingdom
    Cancer Res 61:6413-22. 2001
    ..These results suggest a mechanism of action of CA-4-P in vivo. Combination of CA-4-P with a NOS inhibitor has an additive effect, which it may be possible to exploit therapeutically...
  9. pmc Reduced capacity of tumour blood vessels to produce endothelium-derived relaxing factor: significance for blood flow modification
    G M Tozer
    Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, UK
    Br J Cancer 74:1955-60. 1996
    ..Capacity for EDRF production may represent a difference between tumour and normal tissue blood vessels, which could be exploited for selective pharmacological manipulation of tumour blood flow...
  10. ncbi request reprint Vascular response of tumour and normal tissues to endothelin-1 following antagonism of ET(A) and ET(B) receptors in anaesthetised rats
    K M Bell
    Tumour Microcirculation Group, Mount Vernon Hospital, Northwood, UK
    Int J Cancer 73:283-9. 1997
    ..This contrasts with the majority of normal tissues, in which ET- 1 induces an intense vasoconstriction...
  11. ncbi request reprint Horseradish peroxidase-mediated gene therapy: choice of prodrugs in oxic and anoxic tumor conditions
    O Greco
    Gray Cancer Institute, P. O. Box 100, Northwood, Middlesex HA6 2JR, United Kingdom
    Mol Cancer Ther 1:151-60. 2001
    ..These results indicate that HRP/IAA represents an effective system for enzyme/prodrug-based anticancer approaches, and further improvements could be achieved by the use of novel IAA derivatives...
  12. doi request reprint In vivo characterization of horseradish peroxidase with indole-3-acetic acid and 5-bromoindole-3-acetic acid for gene therapy of cancer
    J Tupper
    Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, UK
    Cancer Gene Ther 17:420-8. 2010
    ..Treatment response could not be improved using different drug scheduling or drug vehicle, nor by combining HRP-directed gene therapy with fractionated radiotherapy...
  13. ncbi request reprint Modification of blood flow in the HSN tumour and normal tissues of the rat by the endothelin ET(B) receptor agonist, IRL 1620
    K M Bell
    Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, UK
    Int J Cancer 80:295-302. 1999
    ..These differences may be exploitable for therapeutic benefit...
  14. ncbi request reprint Limitations of the reporter green fluorescent protein under simulated tumor conditions
    C Coralli
    Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, United Kingdom
    Cancer Res 61:4784-90. 2001
    ..In conclusion, GFP appears to be a good marker gene to study location or movement of proteins or cells but should be used with great caution as a reporter of gene expression under tumor conditions...
  15. pmc The response of tumour vasculature to angiotensin II revealed by its systemic and local administration to 'tissue-isolated' tumours
    G M Tozer
    Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, UK
    Br J Cancer 72:595-600. 1995
    ..A heterogeneous distribution of ATII receptors in the P22 tumour is a more likely explanation for the known heterogeneity of blood flow response to ATII...
  16. ncbi request reprint The influence of nitric oxide on tumour vascular tone
    G M Tozer
    Tumour Microcirculation Group, CRC Gray Laboratory, Mount Vernon Hospital, Northwood, Middlesex, England
    Acta Oncol 34:373-7. 1995
    ..Investigation of endothelium-dependent versus endothelium-independent methods for modifying tumour blood flow may provide methods for further selectivity...
  17. pmc Resistance to flow through tissue-isolated transplanted rat tumours located in two different sites
    P L Sensky
    CRC Gray Laboratory, Mount Vernon Hospital, Northwood, Middlesex, UK
    Br J Cancer 67:1337-41. 1993
    ..The dependence of geometric resistance on tumour site may partly explain why tumours located in different sites respond differently to various forms of therapy...
  18. pmc Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide
    C S Parkins
    Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, HA6 2JR, UK
    Br J Cancer 83:811-6. 2000
    ..The protective effect of NO is probably associated with an anti-neutrophil action...
  19. pmc Use of horseradish peroxidase for gene-directed enzyme prodrug therapy with paracetamol
    J Tupper
    Tumour Microcirculation Group, Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex, HA6 2JR, UK
    Br J Cancer 90:1858-62. 2004
    ..The cytotoxicity was also seen under conditions of severe hypoxia (catalyst induced anoxia), indicating that the HRP/paracetamol combination may be suitable for hypoxia-targeted gene therapy...
  20. pmc Gene delivery to hypoxic cells in vitro
    G U Dachs
    Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, HA6 2JR, UK
    Br J Cancer 83:662-7. 2000
    ..The fact that neither intermediate hypoxia nor intermittent anoxia significantly reduced transfection is promising for future hypoxia-targeted gene therapy strategies...
  21. ncbi request reprint Measuring tumour vascular response to antivascular and antiangiogenic drugs
    G M Tozer
    Tumour Microcirculation Group, Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, UK
    Br J Radiol 76:S23-35. 2003
    ..Finally, the accessibility of vascular end-points for clinical imaging is addressed...
  22. pmc Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies
    Chryso Kanthou
    Cancer Research UK Tumour Microcirculation Group, Section of Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK
    Int J Exp Pathol 90:284-94. 2009
    ..The focus is now to understand mechanisms of susceptibility and resistance to identify novel molecular targets and develop strategies that are more effective...
  23. ncbi request reprint Tumour targeting by microtubule-depolymerizing vascular disrupting agents
    Chryso Kanthou
    University of Sheffield, Cancer Research UK, Tumour Microcirculation Group, School of Medicine and Biomedical Sciences, Beech Hill Road, Sheffi eld, S10 2RX, UK eld ac uk
    Expert Opin Ther Targets 11:1443-57. 2007
    ..This information is essential in order to identify new targets within the tumour vasculature and to improve present therapies...
  24. pmc Characterisation of tumour blood flow using a 'tissue-isolated' preparation
    G M Tozer
    CRC Gray Laboratory, Mount Vernon Hospital, Northwood, Middlesex, UK
    Br J Cancer 70:1040-6. 1994
    ..Tracer methods can be used to obtain additional information on the distribution of blood flow within tumours...
  25. ncbi request reprint Estimation of apparent tumor vascular permeability from multiphoton fluorescence microscopic images of P22 rat sarcomas in vivo
    Constantino Carlos Reyes-Aldasoro
    Academic Unit of Surgical Oncology, The University of Sheffield, Sheffield, UK
    Microcirculation 15:65-79. 2008
    ....
  26. pmc Modification of tumour blood flow using the hypertensive agent, angiotensin II
    G M Tozer
    CRC Gray Laboratory, Mount Vernon Hospital, Northwood, Middlesex, UK
    Br J Cancer 67:981-8. 1993
    ..These results show that some tumours, at least, can respond directly to the effects of vasoactive agents...
  27. ncbi request reprint Nitric oxide in biological fluids: analysis of nitrite and nitrate by high-performance ion chromatography
    S A Everett
    Cancer Research Campaign Gray Laboratory, Mount Vernon Hospital, Northwood, Middlesex, UK
    J Chromatogr A 706:437-42. 1995
    ..Technical problems associated with each method, particularly those arising from nitrate contamination, have been addressed...
  28. ncbi request reprint Semi-automated software for the three-dimensional delineation of complex vascular networks
    P R Barber
    Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, U K
    J Microsc 211:54-62. 2003
    ..The robustness of this algorithm to image smoothing and noise has been investigated...
  29. doi request reprint Measuring the velocity of fluorescently labelled red blood cells with a keyhole tracking algorithm
    C C Reyes-Aldasoro
    Cancer Research UK Tumour Microcirculation Group, Academic Unit of Surgical Oncology, The University of Sheffield, K Floor, School of Medicine and Biomedical Sciences, Sheffield, UK
    J Microsc 229:162-73. 2008
    ....
  30. ncbi request reprint Oxic and anoxic enhancement of radiation-mediated toxicity by horseradish peroxidase/indole-3-acetic acid gene therapy
    O Greco
    Tumour Microcirculation Group, Gray Cancer Institute, PO Box 100, Northwood, Middlesex, HA6 2JR, UK
    Int J Radiat Biol 78:173-81. 2002
    ..To evaluate the interaction of horseradish peroxidase (HRP)/indole-3-acetic acid (IAA) gene therapy with therapeutically relevant doses of radiation...
  31. doi request reprint Kinetic modeling of hyperpolarized (13)C pyruvate metabolism in tumors using a measured arterial input function
    S M Kazan
    CR UK YCR Sheffield Cancer Research Centre, University of Sheffield, Beech Hill Road, Sheffield, UK
    Magn Reson Med 70:943-53. 2013
    ..This provided a robust estimate of kpl, similar to that obtained using a directly measured AIF...
  32. doi request reprint Quantitative estimation of tissue blood flow rate
    Gillian M Tozer
    Academic Unit of Surgical Oncology, University of Sheffield, School of Medicine and Biomedical Sciences, Sheffield, UK
    Methods Mol Biol 467:271-86. 2009
    ..The experimental procedures and analytical methods for both techniques are given, as well as guidelines for choosing the most appropriate method...
  33. doi request reprint Application of intravital microscopy in studies of tumor microcirculation
    Sarah Jane Lunt
    University of Sheffield, School of Medicine, Department of Oncology, Sheffield, United Kingdom
    J Biomed Opt 15:011113. 2010
    ..g., confocal microscopy, multiphoton microscopy, hyperspectral imaging, and optical coherence tomography) with examples of their application to studies of tumor angiogenesis...
  34. pmc The biology of the combretastatins as tumour vascular targeting agents
    Gillian M Tozer
    Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, UK
    Int J Exp Pathol 83:21-38. 2002
    ..This paper reviews the current understanding of the mechanism of action of the combretastatins and their therapeutic potential...
  35. ncbi request reprint Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging
    Susan M Galbraith
    Department of Medical Oncology, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
    J Clin Oncol 21:2831-42. 2003
    ..Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) studies were performed to examine changes in parameters related to blood flow and vascular permeability in tumor and normal tissue after CA4P treatment. Materials and..
  36. ncbi request reprint Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down
    Katharine J Lankester
    Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middx, UK
    Int J Oncol 30:453-60. 2007
    ..These results demonstrate that moderate tumor blood flow reduction following antibody administration is sufficient to improve tumor antibody retention. This is encouraging for the combination of CA-4-P and 131I-A5B7 in clinical trials...
  37. ncbi request reprint The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells
    Chryso Kanthou
    Tumour Microcirculation Group, Gray Cancer Institute, Mount Vernon Hospital, PO Box 100, Northwood, Middlesex HA6 2JR, UK
    Blood 99:2060-9. 2002
    ....
  38. ncbi request reprint Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI
    Ross J Maxwell
    Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, UK
    NMR Biomed 15:89-98. 2002
    ..These results suggest that K(trans) values for Gd-DTPA uptake into tumours could be a useful non-invasive indicator of blood flow changes induced by anti-vascular agents such as combretastatin...
  39. ncbi request reprint Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models
    Sally A Hill
    Tumour Microcirculation Group, Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
    Int J Cancer 102:70-4. 2002
    ..It did not do so in the spontaneous T138 tumour model. These studies indicate that the potential anti-tumour activity of CA4P when used as a single agent in clinical trials may be enhanced when used in multiple dose schedules...
  40. ncbi request reprint From bench to bedside for gene-directed enzyme prodrug therapy of cancer
    Gabi U Dachs
    Angiogenesis Research Group, Department of Pathology, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
    Anticancer Drugs 16:349-59. 2005
    ....
  41. ncbi request reprint Enhancement of vascular targeting by inhibitors of nitric oxide synthase
    Peter D Davis
    Angiogene Pharmaceuticals Ltd, England, Oxford, UK
    Int J Radiat Oncol Biol Phys 54:1532-6. 2002
    ..This study investigates the enhancement of the vascular targeting activity of the tubulin-binding agent combretastatin A4 phosphate (CA4P) by various inhibitors of nitric oxide synthases...
  42. ncbi request reprint Therapeutic targeting of the tumor vasculature
    Gillian M Tozer
    Tumour Microcirculation Group, Gray Cancer Institute, Mount Vernon Hospital Middlesex, United Kingdom
    Semin Radiat Oncol 14:222-32. 2004
    ....
  43. ncbi request reprint ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature
    Peter D Davis
    Angiogene Pharmaceuticals Ltd, Oxford Science Park, Oxford, United Kingdom
    Cancer Res 62:7247-53. 2002
    ..These findings show that ZD6126 is a promising antivascular agent for the treatment of solid tumors...
  44. ncbi request reprint The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses
    Vivien E Prise
    Tumor Microcirculation Group, Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middx HA6 2JR, UK
    Int J Oncol 21:717-26. 2002
    ..It is currently being used to aid interpretation of pharmacodynamic data obtained from phase I/II clinical trials of CA-4-P and is relevant for future drug development in this area...
  45. ncbi request reprint Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy
    Gillian M Tozer
    Tumour Microcirculation Group, Gray Cancer Institute, P O Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, UK
    Adv Drug Deliv Rev 57:135-52. 2005
    ..Here, we review the current status of this work and provide some examples of its use for studying the dynamics of tumour angiogenesis and vascular function...
  46. ncbi request reprint The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro
    Andrew C Brooks
    Tumour Microcirculation Group, Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middx HA6 2JR, U K
    Anticancer Res 23:3199-206. 2003
    ..In vivo, CA-4-P causes rapid shutdown of tumour blood flow (within minutes) and a significant neutrophil infiltration at later times...
  47. ncbi request reprint Radiation effects on the cytoskeleton of endothelial cells and endothelial monolayer permeability
    Dorota Gabrys
    Department of Radiation Oncology, Maria Skłodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland
    Int J Radiat Oncol Biol Phys 69:1553-62. 2007
    ..To investigate the effects of radiation on the endothelial cytoskeleton and endothelial monolayer permeability and to evaluate associated signaling pathways, which could reveal potential mechanisms of known vascular effects of radiation...
  48. ncbi request reprint Effects of tin-protoporphyrin IX on blood flow in a rat tumor model
    Amel F Khelifi
    Tumor Microcirculation Group, Gray Cancer Institute, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, United Kingdom
    Exp Biol Med (Maywood) 228:481-5. 2003
    ..The results also highlight the potential usefulness of CuPP as a tumor blood flow modifier...
  49. ncbi request reprint Effective gene transfer to solid tumors using different nonviral gene delivery techniques: electroporation, liposomes, and integrin-targeted vector
    Maja Cemazar
    Tumor Microcirculation Group, Gray Cancer Institute, Mount Vernon Hospital, Northwood HA6 2JR, UK
    Cancer Gene Ther 9:399-406. 2002
    ..In conclusion, our results demonstrate that some nonviral methods of gene delivery are feasible and efficient in transfecting solid tumors. Therefore, this makes nonviral methods attractive for further development...
  50. ncbi request reprint Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy
    Beatrice M Seddon
    Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, United Kingdom
    Clin Cancer Res 8:2323-35. 2002
    ..We present validation studies of SR-4554 as a noninvasive hypoxia marker detected by fluorine-19 magnetic resonance spectroscopy ((19)F MRS) in the P22 carcinosarcoma, a tumor with clinically relevant hypoxia levels...
  51. ncbi request reprint Targeting cancer with gene therapy using hypoxia as a stimulus
    Gabi U Dachs
    Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, UK
    Methods Mol Med 90:371-87. 2004